Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company that discovers and develops cell therapies for cancer treatment, primarily in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T therapy in Phase I trials for multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T therapy in Phase I trials for adult B cell acute lymphoblastic leukemia (B-ALL) and relapsed or refractory (r/r) B-ALL; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T therapy in Phase I trials for adult T cell acute lymphoblastic leukemia. Additional candidates include GC007g, a donor-derived CD19-directed allogeneic CAR-T therapy in Phase 2 trials for r/r B-ALL, and GC502, a TruUCAR-enabled dual CD19- and CD7-directed off-the-shelf allogeneic CAR-T therapy in Phase I trials for B-cell malignancies. The company also has earlier-stage candidates targeting hematologic malignancies and solid tumors. Incorporated in 2017 and headquartered in Suzhou, China, Gracell Biotechnologies Inc. has operated as a subsidiary of AstraZeneca Treasury Limited since February 22, 2024.